Novartis (NVS)
(Real Time Quote from BATS)
$116.77 USD
+0.35 (0.30%)
Updated Sep 25, 2024 02:24 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Price, Consensus and EPS Surprise
NVS 116.77 +0.35(0.30%)
Will NVS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NVS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVS
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
NVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Other News for NVS
Perspective draws buy at Truist on radiopharma potential
Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2024 Commentary
Janus Henderson European Focus Fund Q2 2024 Commentary
UCB gets expanded FDA approval for psoriasis drug Bimzelx
Novartis' Pluvicto expected to dominate prostate cancer radiopharmaceutical market